<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669470</url>
  </required_header>
  <id_info>
    <org_study_id>08_RVO-FNOs_2020</org_study_id>
    <nct_id>NCT04669470</nct_id>
  </id_info>
  <brief_title>Bariatric Endoscopy and NAFLD</brief_title>
  <official_title>Influence of Bariatric Endoscopy on Clinical Course of NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Olomouc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Palacky University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Find out how bariatric endocopy will influence clinical course of non alcoholic fatty liver&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will test and investigate the impact of bariatric endoscopy (various types of&#xD;
      intragastric balloons, endoscopic sleeve gastroplasty, aspiration therapy) on components of&#xD;
      the metabolic syndrome in obese patients, especially on influencing non-alcoholic steatosis&#xD;
      and steatohepatitis and signs of liver fibrotization and weight reduction. The method&#xD;
      consists in performing a mini-invasive endoscopic procedure and, as a result, in reduced food&#xD;
      intake.&#xD;
&#xD;
      Current state of knowledge:&#xD;
&#xD;
      Based on data evaluated according to EBM (Evidence Based Medicine), it is an indisputable&#xD;
      fact that bariatric methods have a demonstrable effect not only on improving the parameters&#xD;
      and regression of many metabolic syndromes, but also improve the course of non-alcoholic&#xD;
      fatty liver disease (NAFLD). It is this nosological unit that is becoming the dominant cause&#xD;
      of liver disease in developed countries and has two subunits, where simple hepatic steatosis&#xD;
      (NAFL) is considered a benign disease, while the second, where fat accumulation in the liver&#xD;
      is associated with the inflammatory process called non-alcoholic steatohepatitis (NASH). )&#xD;
      has serious consequences for the liver with the development of fibrotization leading to&#xD;
      cirrhosis with all its adverse effects. Recently, however, it has been shown that even simple&#xD;
      steatosis is not as benign as it seemed, but carries an independent risk for the patient due&#xD;
      to an increased incidence of cardiovascular diseases, oncological manifestations and a higher&#xD;
      incidence of metabolic syndrome manifestations. Classical bariatric endoscopy carries a&#xD;
      number of risks associated with the patient for the surgical procedure, however, we also have&#xD;
      less invasive methods of gradually more and more developing endoscopy and dreams of&#xD;
      associated bariatric procedures with many times lower risk for the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of patients with NAFLD with degree of fibrosis of the liver amog patients undergoing bariatric endoscopy and determine influence of bariatric endoscopy on clinical course of NAFLD and liver fibrosis</measure>
    <time_frame>24 months</time_frame>
    <description>Amount of patients with NAFLD with degree of fibrosis of the liver amog patients undergoing bariatric endoscopy and determine influence of bariatric endoscopy on clinical course of NAFLD and liver fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of bariatric endoscopy on improvements of weight, antropometric, improvements in components of metabolic syndrome</measure>
    <time_frame>24 months</time_frame>
    <description>Influence of bariatric endoscopy on improvements of weight, antropometric, improvements in components of metabolic syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity</condition>
  <condition>NAFLD</condition>
  <condition>Liver Steatosis</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Group with adjustable IGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group with nin-adjustable IGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bariatric endoscopy, mainly intragastric baloons, plication of stomach too</intervention_name>
    <description>bariatric endoscopy, mainly intragastric baloons, plication of stomach too</description>
    <arm_group_label>Group with adjustable IGB</arm_group_label>
    <arm_group_label>Group with nin-adjustable IGB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for participation in this study, subjects must conform to the following&#xD;
        inclusion criteria:&#xD;
&#xD;
          1. Age between 21-64 years;&#xD;
&#xD;
          2. BMI &gt;30 Kg/m2&#xD;
&#xD;
          3. Must be able to comply with all study requirements for the duration of the study as&#xD;
             outlined in the protocol. This includes complying with the visit schedule as well as&#xD;
             study specific procedures such as: clinical assessment , endoscopy, radiography, as&#xD;
             well as laboratory investigations.&#xD;
&#xD;
          4. Must be able to understand and be willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects meeting any of the following exclusionary criteria cannot be enrolled in the&#xD;
             study:&#xD;
&#xD;
               1. Achalasia and any other esophageal motility disorders&#xD;
&#xD;
               2. Heart diseases: unstable angina, myocardial infarction within the past year, or&#xD;
                  heart disease classified within the New York Heart Association's Class III or IV&#xD;
                  functional capacity.&#xD;
&#xD;
               3. Hypertension: uncontrolled hypertension during last 3 month&#xD;
&#xD;
               4. Severe renal, hepatic, pulmonary disease or cancer;&#xD;
&#xD;
               5. GIT stenosis or obstruction&#xD;
&#xD;
               6. Pregnancy or breastfeeding&#xD;
&#xD;
               7. Impending gastric surgery 60 days post intervention;&#xD;
&#xD;
               8. Currently participating in other study&#xD;
&#xD;
               9. Celiac disease&#xD;
&#xD;
              10. History of bariatric surgery&#xD;
&#xD;
              11. Chronic or recent acute pancreatitis&#xD;
&#xD;
              12. Type 2 diabetes with insuline medication or type 1 diabetes&#xD;
&#xD;
              13. Hematologic disease or disease with impairment of hemocoagulation&#xD;
&#xD;
              14. Decompensated psychiatric disease&#xD;
&#xD;
              15. Autoimmune disease with chronic glucocorticoid or imunosupressive medications&#xD;
&#xD;
              16. Uncontroled disease of thyroid gland&#xD;
&#xD;
              17. Excesive abuse of addictive substances such alcohol or other&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Vasura, MD</last_name>
    <role>Study Chair</role>
    <affiliation>- Department of gastroenterology, hepatology and pancreatology, Internal clinic, University hospital Ostrava</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evzen Machytka</last_name>
    <role>Study Chair</role>
    <affiliation>Department of gastroenterology, hepatology and pancreatology, Internal clinic, University hospital Ostrava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Vasura</last_name>
    <phone>420597374191</phone>
    <email>obezita@fno.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of gastroenterology, hepatology and pancreatology</name>
      <address>
        <city>Ostrava</city>
        <zip>70800</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Vasura</last_name>
      <phone>+420597374191</phone>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Fakhry TK, Mhaskar R, Schwitalla T, Muradova E, Gonzalvo JP, Murr MM. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019 Mar;15(3):502-511. doi: 10.1016/j.soard.2018.12.002. Epub 2018 Dec 6.</citation>
    <PMID>30683512</PMID>
  </reference>
  <reference>
    <citation>Machytka E, Klvana P, Kornbluth A, Peikin S, Mathus-Vliegen LE, Gostout C, Lopez-Nava G, Shikora S, Brooks J. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011 Oct;21(10):1499-507. doi: 10.1007/s11695-011-0424-z.</citation>
    <PMID>21553304</PMID>
  </reference>
  <reference>
    <citation>Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018 Aug 14;24(30):3361-3373. doi: 10.3748/wjg.v24.i30.3361. Review.</citation>
    <PMID>30122876</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>NAFLD</keyword>
  <keyword>liver steatosis</keyword>
  <keyword>liver fibrosis</keyword>
  <keyword>bariatric endoscopy</keyword>
  <keyword>weight lose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

